<H1>Chapter DOI: 10.1007/978-1-60327-829-4_27<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>124</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>123</td></tr><tr><td>BibStructured Count</td><td width="10%">116</td></tr><tr><td>BibUnstructured Count</td><td width="10%">8</td></tr><tr><td>DOI already available in SpringerLink</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>82</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>81</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>82</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>73</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_27</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, Author_FamilyName_1, FirstPage, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR2_27</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, ArticleTitle, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR3_27</td><td>BibArticle</td><td>Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294(2):238&#8211;44.</td><td><a href=http://dx.doi.org/10.1001/jama.294.2.238>10.1001/jama.294.2.238</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, Author_FamilyName_1, FirstPage, ArticleTitle, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR4_27</td><td>BibArticle</td><td>Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics &#8211; theory. Urology 1981;17 Suppl 3:40&#8211;53.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5_27</td><td>BibArticle</td><td>Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62(15):4427&#8211;33.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6_27</td><td>BibArticle</td><td>Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003;30(5):649&#8211;58.</td><td><a href=http://dx.doi.org/10.1016/S0093-7754(03)00350-6>10.1016/S0093-7754(03)00350-6</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, ArticleTitle, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR7_27</td><td>BibArticle</td><td>Chakraborty NG, Stevens RL, Mehrotra S, et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 2003;52(8):497&#8211;505.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_27</td><td>BibArticle</td><td>Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145(5):907&#8211;23.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1001/jama.1992.03480160094042>10.1001/jama.1992.03480160094042</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR9_27</td><td>BibArticle</td><td>Madan RA, Gulley JL, Arlen PM. PSA-based vaccines for the treatment of prostate cancer. Expert Rev Vaccines 2006;5(2):199&#8211;209.</td><td><a href=http://dx.doi.org/10.1586/14760584.5.2.199>10.1586/14760584.5.2.199</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR10_27</td><td>BibArticle</td><td>Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83(11):2259&#8211;69.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-0142(19981201)83:11%3C2259::AID-CNCR5%3E3.3.CO;2-K>10.1002/(SICI)1097-0142(19981201)83:11%3C2259::AID-CNCR5%3E3.3.CO;2-K</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, FirstPage, Author_FamilyName_1, JournalTitle, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR11_27</td><td>BibArticle</td><td>Wright Jr GL, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996;48(2):326&#8211;34.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(96)00184-7>10.1016/S0090-4295(96)00184-7</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, JournalTitle, ArticleTitle, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR12_27</td><td>BibArticle</td><td>Veeramani S, Yuan TC, Chen SJ, et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer 2005;12(4):805&#8211;22.</td><td><a href=http://dx.doi.org/10.1677/erc.1.00950>10.1677/erc.1.00950</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR13_27</td><td>BibArticle</td><td>Vihko P, Virkkunen P, Henttu P, Roiko K, Solin T, Huhtala ML. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 1988;236(2):275&#8211;81.</td><td><a href=http://dx.doi.org/10.1016/0014-5793(88)80037-1>10.1016/0014-5793(88)80037-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR14_27</td><td>BibArticle</td><td>Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996;88(1):202&#8211;10.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_27</td><td>BibArticle</td><td>Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90(8):3539&#8211;43.</td><td><a href=http://dx.doi.org/10.1073/pnas.90.8.3539>10.1073/pnas.90.8.3539</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR16_27</td><td>BibArticle</td><td>Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987;139(4):1113&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_27</td><td>BibArticle</td><td>Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5(7):1738&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_27</td><td>BibArticle</td><td>Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62(20):5770&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_27</td><td>BibArticle</td><td>Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61(11):4497&#8211;505.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20_27</td><td>BibArticle</td><td>Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61(1):206&#8211;14.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_27</td><td>BibArticle</td><td>Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 2007;7(12):1893&#8211;902.</td><td><a href=http://dx.doi.org/10.1517/14712598.7.12.1893>10.1517/14712598.7.12.1893</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, FirstPage, Author_FamilyName_1, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR22_27</td><td>BibArticle</td><td>Wingren AG, Parra E, Varga M, et al. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995;15(3&#8211;4):235&#8211;53.</td><td><a href=http://dx.doi.org/10.1615/CritRevImmunol.v15.i3-4.30>10.1615/CritRevImmunol.v15.i3-4.30</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, FirstPage, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR23_27</td><td>BibArticle</td><td>Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007;25 Suppl 2:B89&#8211;96.</td><td><a href=http://dx.doi.org/10.1016/j.vaccine.2007.04.091>10.1016/j.vaccine.2007.04.091</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, VolumeID, FirstPage, Author_FamilyName_1, JournalTitle, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR24_27</td><td>BibArticle</td><td>Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007;12:4957&#8211;71.</td><td><a href=http://dx.doi.org/10.2741/2441>10.2741/2441</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR25_27</td><td>BibArticle</td><td>Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98(25):14565&#8211;70.</td><td><a href=http://dx.doi.org/10.1073/pnas.251140998>10.1073/pnas.251140998</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR26_27</td><td>BibArticle</td><td>Matejuk A, Hopke C, Vandenbark AA, Hurn PD, Offner H. Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J Immunol 2005;174(4):2387&#8211;95.</td><td><a href=http://dx.doi.org/10.4049/jimmunol.174.4.2387>10.4049/jimmunol.174.4.2387</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, FirstPage, Author_FamilyName_1, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR27_27</td><td>BibArticle</td><td>Goldberg GL, Sutherland JS, Hammet MV, et al. Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation 2005;80(11):1604&#8211;13.</td><td><a href=http://dx.doi.org/10.1097/01.tp.0000183962.64777.da>10.1097/01.tp.0000183962.64777.da</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, ArticleTitle, Author_FamilyName_2, JournalTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR28_27</td><td>BibArticle</td><td>Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005;7(3):239&#8211;49.</td><td><a href=http://dx.doi.org/10.1016/j.ccr.2005.01.027>10.1016/j.ccr.2005.01.027</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, JournalTitle, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR29_27</td><td>BibArticle</td><td>Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005;175(4):2741&#8211;53.</td><td><a href=http://dx.doi.org/10.4049/jimmunol.175.4.2741>10.4049/jimmunol.175.4.2741</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR30_27</td><td>BibArticle</td><td>Lin AM, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol 2008;20(3):294&#8211;9.</td><td><a href=http://dx.doi.org/10.1097/CCO.0b013e3282f8b075>10.1097/CCO.0b013e3282f8b075</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR31_27</td><td>BibArticle</td><td>Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003;170(12):6338&#8211;47.</td><td><a href=http://dx.doi.org/10.4049/jimmunol.170.12.6338>10.4049/jimmunol.170.12.6338</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR32_27</td><td>BibArticle</td><td>Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64(21):7985&#8211;94.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-1525>10.1158/0008-5472.CAN-04-1525</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR33_27</td><td>BibArticle</td><td>Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8(19):1765&#8211;80.</td><td><a href=http://dx.doi.org/10.2174/1381612023394089>10.2174/1381612023394089</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, ArticleTitle, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR34_27</td><td>BibArticle</td><td>Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11(9):3353&#8211;62.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-2062>10.1158/1078-0432.CCR-04-2062</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR35_27</td><td>BibArticle</td><td>AbdAlla EE, Blair GE, Jones RA, Sue-Ling HM, Johnston D. Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. J Natl Cancer Inst 1995;87(7):489&#8211;96.</td><td><a href=http://dx.doi.org/10.1093/jnci/87.7.489>10.1093/jnci/87.7.489</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR36_27</td><td>BibArticle</td><td>Fisk B, Ioannides CG. Increased sensitivity of adriamycin-selected tumor lines to CTL-mediated lysis results in enhanced drug sensitivity. Cancer Res 1998;58(21):4790&#8211;3.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR37_27</td><td>BibArticle</td><td>Aquino A, Prete SP, Greiner JW, et al. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 1998;4(10):2473&#8211;81.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38_27</td><td>BibArticle</td><td>Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J. Cisplatin induces fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology 2000;59(4):336&#8211;43.</td><td><a href=http://dx.doi.org/10.1159/000012192>10.1159/000012192</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, JournalTitle, Author_FamilyName_2, ArticleTitle, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR39_27</td><td>BibArticle</td><td>Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14(11):3536&#8211;44.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-4025>10.1158/1078-0432.CCR-07-4025</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, Author_FamilyName_2, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR40_27</td><td>BibArticle</td><td>Orsini F, Pavelic Z, Mihich E. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 1977;37(6):1719&#8211;26.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR41_27</td><td>BibArticle</td><td>Maccubbin DL, Wing KR, Mace KF, Ho RL, Ehrke MJ, Mihich E. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 1992;52(13):3572&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR42_27</td><td>BibArticle</td><td>Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000;49(4&#8211;5):181&#8211;5.</td><td><a href=http://dx.doi.org/10.1007/s002620000122>10.1007/s002620000122</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR43_27</td><td>BibArticle</td><td>Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105(7):2862&#8211;8.</td><td><a href=http://dx.doi.org/10.1182/blood-2004-06-2410>10.1182/blood-2004-06-2410</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, JournalTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR44_27</td><td>BibArticle</td><td>Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201(10):1591&#8211;602.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1084/jem.20042167>10.1084/jem.20042167</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR45_27</td><td>BibArticle</td><td>Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12(4):1260&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-2059>10.1158/1078-0432.CCR-05-2059</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR46_27</td><td>BibArticle</td><td>Gribben JG, Ryan DP, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11(12):4430&#8211;6.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-2111>10.1158/1078-0432.CCR-04-2111</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR47_27</td><td>BibArticle</td><td>Antonia SJ, Mirza N, Fricke I, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12(3 Pt 1):878&#8211;87.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-2013>10.1158/1078-0432.CCR-05-2013</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR48_27</td><td>BibArticle</td><td>Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor &#8211; secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13(13):3883&#8211;91.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-2937>10.1158/1078-0432.CCR-06-2937</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, Author_FamilyName_1, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR49_27</td><td>BibArticle</td><td>Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989;7:445&#8211;80.</td><td><a href=http://dx.doi.org/10.1146/annurev.iy.07.040189.002305>10.1146/annurev.iy.07.040189.002305</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR50_27</td><td>BibArticle</td><td>Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270(5238):985&#8211;8.</td><td><a href=http://dx.doi.org/10.1126/science.270.5238.985>10.1126/science.270.5238.985</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, ArticleTitle, JournalTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR51_27</td><td>BibArticle</td><td>Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271(5256):1734&#8211;6.</td><td><a href=http://dx.doi.org/10.1126/science.271.5256.1734>10.1126/science.271.5256.1734</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, ArticleTitle, Author_FamilyName_2, JournalTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR52_27</td><td>BibArticle</td><td>Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116(7):1935&#8211;45.</td><td><a href=http://dx.doi.org/10.1172/JCI27745>10.1172/JCI27745</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, ArticleTitle, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR53_27</td><td>BibArticle</td><td>Zeh III HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162(2):989&#8211;94.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR54_27</td><td>BibArticle</td><td>Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174(10):5994&#8211;6004.</td><td><a href=http://dx.doi.org/10.4049/jimmunol.174.10.5994>10.4049/jimmunol.174.10.5994</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR55_27</td><td>BibArticle</td><td>Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3(7):611&#8211;8.</td><td><a href=http://dx.doi.org/10.1038/ni0702-611>10.1038/ni0702-611</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR56_27</td><td>BibArticle</td><td>Allison JP, Chambers C, Hurwitz A, et al. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found Symp 1998;215:92&#8211;8. Discussion 8&#8211;102, 86&#8211;90.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/9780470515525.ch7>10.1002/9780470515525.ch7</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR57_27</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gerritsen</span> <span style='background:#DDDDDD'>W</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#FFFF80'>Van Den</span> <span style='background:#BCBCBC'>Eertwegh</span> <span style='background:#DDDDDD'>A</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#FFFF80'>De</span> <span style='background:#BCBCBC'>Gruijl</span> <span style='background:#DDDDDD'>T</span></span>, et al.</aug> A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with fully human anti-CTL4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC) [abstract]. ASCO Prostate Cancer Symposium <span style='background:#66FF66'>2007</span>:<span style='background:#D279FF'>262</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR58_27</td><td>BibArticle</td><td>Gerritsen W, Van Den Eertwegh A, De Gruijl T. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) [abstract]. J Clin Oncol 2008;26(Suppl):5146.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR59_27</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Gulley</span> <span style='background:#DDDDDD'>J</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Arlen</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Madan</span> <span style='background:#DDDDDD'>R</span></span>, et al.</aug> Phase I trial of a PSA based vaccine and ipilimumab in patients (pts) with metastatic castrate resistant prostate cancer (CRPC) [abstract]. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics Meeting Abstracts. October <span style='background:#66FF66'>2007</span>:<span style='background:#FFFF0F'>A142</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR60_27</td><td>BibArticle</td><td>Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther 2004;4(4):575&#8211;88.</td><td><a href=http://dx.doi.org/10.1517/14712598.4.4.575>10.1517/14712598.4.4.575</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, Author_FamilyName_2, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR61_27</td><td>BibArticle</td><td>Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59(3):676&#8211;83.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR62_27</td><td>BibArticle</td><td>Kantor J, Abrams S, Irvine K, Snoy P, Kaufman H, Schlom J. Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann N Y Acad Sci 1993;690:370&#8211;3.</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.1993.tb44034.x>10.1111/j.1749-6632.1993.tb44034.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, ArticleTitle, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR63_27</td><td>BibArticle</td><td>Hodge JW, Grosenbach DW, Rad AN, Giuliano M, Sabzevari H, Schlom J. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 2001;19(25&#8211;26):3552&#8211;67.</td><td><a href=http://dx.doi.org/10.1016/S0264-410X(01)00062-7>10.1016/S0264-410X(01)00062-7</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR64_27</td><td>BibArticle</td><td>Zhu M, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001;61(9):3725&#8211;34.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR65_27</td><td>BibArticle</td><td>Palena C, Zhu M, Schlom J, Tsang KY. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells. Blood 2004;104(1):192&#8211;9.</td><td><a href=http://dx.doi.org/10.1182/blood-2003-09-3211>10.1182/blood-2003-09-3211</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1, JournalTitle, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR66_27</td><td>BibArticle</td><td>Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 1996;93(21):11341&#8211;8.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.21.11341>10.1073/pnas.93.21.11341</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR67_27</td><td>BibArticle</td><td>Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 2002;53(2):109&#8211;17.</td><td><a href=http://dx.doi.org/10.1002/pros.10130>10.1002/pros.10130</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR68_27</td><td>BibArticle</td><td>Etlinger HM, Altenburger W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine 1991;9(7):470&#8211;2.</td><td><a href=http://dx.doi.org/10.1016/0264-410X(91)90030-A>10.1016/0264-410X(91)90030-A</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, JournalTitle, Author_FamilyName_2, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR69_27</td><td>BibArticle</td><td>Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993;11(11):1154&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/0264-410X(93)90079-D>10.1016/0264-410X(93)90079-D</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, JournalTitle, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR70_27</td><td>BibArticle</td><td>Konishi E, Pincus S, Paoletti E, Shope RE, Wason PW. Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine 1994;12(7):633&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR71_27</td><td>BibArticle</td><td>Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15(6&#8211;7):759&#8211;68.</td><td><a href=http://dx.doi.org/10.1016/S0264-410X(96)00238-1>10.1016/S0264-410X(96)00238-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR72_27</td><td>BibArticle</td><td>Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18(23):3964&#8211;73.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR73_27</td><td>BibArticle</td><td>Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122&#8211;32.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.08.083>10.1200/JCO.2004.08.083</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR74_27</td><td>BibArticle</td><td>Kaufman H, Wang W, Manola J, DiPaola R. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone-dependent prostate cancer: follow-up clinical results from ECOG 7897 [abstract]. J Clin Oncol 2005;23(16S):4501.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR75_27</td><td>BibArticle</td><td>Lechleider RJ, Arlen PM, Tsang KY, et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin-2 is used as an adjuvant. Clin Cancer Res 2008;14(16):5284&#8211;91.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-5162>10.1158/1078-0432.CCR-07-5162</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR76_27</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Clinical Trials (PDQ)</span>. <span style='background:#FFD9B3'>Samarium Sm 153 lexidronam pentasodium with or without vaccine therapy and GM-CSF in treating patients with prostate cancer and bone metastases</span>. <span style='background:#FFFF0F'>Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=535561&version=patient&protocolsearchid=4937826. Accessed Jul 2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR77_27</td><td>BibArticle</td><td>Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005;174(2):539&#8211;46.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000165159.33772.5b>10.1097/01.ju.0000165159.33772.5b</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, Author_FamilyName_2, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR78_27</td><td>BibArticle</td><td>Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14(14):4526&#8211;31.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-5048>10.1158/1078-0432.CCR-07-5048</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, FirstPage, Author_FamilyName_1, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR79_27</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Clinical Trials (PDQ)</span>. <span style='background:#FFD9B3'>Flutamide with or without vaccine therapy in treating patients with nonmetastatic prostate cancer</span>. <span style='background:#FFFF0F'>Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=535593&version=patient&protocolsearchid=4937826. Accessed Jul 2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR80_27</td><td>BibArticle</td><td>Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59(22):5800&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR81_27</td><td>BibArticle</td><td>Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007;178(4 Pt 1):1515&#8211;20.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2007.05.117>10.1016/j.juro.2007.05.117</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR82_27</td><td>BibArticle</td><td>Kantoff P, Glode L, Tannenbaum S, Bilhartz D. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients with hormone-refractory prostate cancer [abstract]. J Clin Oncol 2005;24(18S):1501.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR83_27</td><td>BibArticle</td><td>Madan R, Gulley J, Dahut W, et al. Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): implications for clinical trial design [abstract]. J Clin Oncol 2008;16(20S):3005.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR84_27</td><td>BibArticle</td><td>Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(7):1232&#8211;7.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.06.100>10.1200/JCO.2003.06.100</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR85_27</td><td>BibArticle</td><td>Rini BI. Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther 2002;4(1):76&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR86_27</td><td>BibArticle</td><td>Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008;42(1):91&#8211;8.</td><td><a href=http://dx.doi.org/10.1345/aph.1K429>10.1345/aph.1K429</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle, VolumeID, IssueID</td><td>CrossRef</td></tr><tr><td>CR87_27</td><td>BibArticle</td><td>Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6(6):2175&#8211;82.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR88_27</td><td>BibArticle</td><td>Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18(23):3894&#8211;903.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR89_27</td><td>BibArticle</td><td>Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate 2004;60(3):197&#8211;204.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/pros.20040>10.1002/pros.20040</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR90_27</td><td>BibArticle</td><td>Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089&#8211;94.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.04.5252>10.1200/JCO.2005.04.5252</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR91_27</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>US</span> <span style='background:#BCBCBC'>Food</span></span> and <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#DDDDDD'>Drug Administration</span>, <span style='background:#BCBCBC'>Cellular</span></span></aug>, <span style='background:#FFD9B3'>Tissue and Gene Therapies Advisory Committee</span>. Sipuleucel-T briefing document. Dendreon Corporation. <span style='background:#FFFF0F'>Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf. Accessed Jul 2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR92_27</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Dendreon expects interim data analysis for phase 3 PROVENGE</span> IMPACT Trial in October. <span style='background:#FFFF0F'>Available from: http://www.investor.dendreon.com/newsroom/releasedetail.cfm?ReleaseID=323910&header=News. Accessed Aug 2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR93_27</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Clinical Trials (PDQ)</span>. <span style='background:#FFD9B3'>Sipuleucel-T as neoadjuvant treatment in prostate cancer</span>. <span style='background:#FFFF0F'>Available from: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=601177&version=HealthProfessional&protocolsearchid=5006778. Accessed Aug 2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR94_27</td><td>BibArticle</td><td>Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59(20):5160&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR95_27</td><td>BibArticle</td><td>Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006;12(11 Pt 1):3394&#8211;401.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-0145>10.1158/1078-0432.CCR-06-0145</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR96_27</td><td>BibArticle</td><td>Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113:975&#8211;84.</td><td><a href=http://dx.doi.org/10.1002/cncr.23669>10.1002/cncr.23669</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR97_27</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Cell Genesys, Inc</span>. <span style='background:#FFD9B3'>GVAX immunotherapy for prostate cancer</span>. <span style='background:#FFFF0F'>Available from: http://www.cellgenesys.com/clinical-prostate-cancer.shtml. Accessed Aug 2008</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR98_27</td><td>BibArticle</td><td>Eaton JD, Perry MJ, Nicholson S, et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002;89(1):19&#8211;26.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410X.2002.02572.x>10.1046/j.1464-410X.2002.02572.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, FirstPage, Author_FamilyName_1, VolumeID, IssueID</td><td>CrossRef</td></tr><tr><td>CR99_27</td><td>BibArticle</td><td>Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005;11(12):4469&#8211;78.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-2337>10.1158/1078-0432.CCR-04-2337</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, FirstPage, Author_FamilyName_1, Year, IssueID, VolumeID</td><td>CrossRef</td></tr><tr><td>CR100_27</td><td>BibArticle</td><td>Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155(3):1151&#8211;64.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR101_27</td><td>BibArticle</td><td>Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2002;2(8):827&#8211;34.</td><td><a href=http://dx.doi.org/10.1517/14712598.2.8.827>10.1517/14712598.2.8.827</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR102_27</td><td>BibArticle</td><td>Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0092-8674(00)80856-9>10.1016/S0092-8674(00)80856-9</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, JournalTitle, Author_FamilyName_1, FirstPage, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR103_27</td><td>BibArticle</td><td>Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167(3):1137&#8211;40.</td><td><a href=http://dx.doi.org/10.4049/jimmunol.167.3.1137>10.4049/jimmunol.167.3.1137</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>IssueID, Year, VolumeID, Author_FamilyName_2, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR104_27</td><td>BibArticle</td><td>Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168(9):4272&#8211;6.</td><td><a href=http://dx.doi.org/10.4049/jimmunol.168.9.4272>10.4049/jimmunol.168.9.4272</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR105_27</td><td>BibArticle</td><td>Fu T, Shen Y, Fujimoto S. Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice. Int J Cancer 2000;87(5):680&#8211;7.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/1097-0215(20000901)87:5%3C680::AID-IJC10%3E3.3.CO;2-G>10.1002/1097-0215(20000901)87:5%3C680::AID-IJC10%3E3.3.CO;2-G</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, FirstPage, Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR106_27</td><td>BibArticle</td><td>Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34(2):336&#8211;44.</td><td><a href=http://dx.doi.org/10.1002/eji.200324181>10.1002/eji.200324181</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, ArticleTitle, Author_FamilyName_2, VolumeID, IssueID, Year</td><td>CrossRef</td></tr><tr><td>CR107_27</td><td>BibArticle</td><td>Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/nm1093>10.1038/nm1093</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, FirstPage, Author_FamilyName_1, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR108_27</td><td>BibArticle</td><td>Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102(51):18538&#8211;43.</td><td><a href=http://dx.doi.org/10.1073/pnas.0509182102>10.1073/pnas.0509182102</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, ArticleTitle, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR109_27</td><td>BibArticle</td><td>Kawaida H, Kono K, Takahashi A, et al. Distribution of CD4+CD25 high regulatory T cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res 2005;124(1):151&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR110_27</td><td>BibArticle</td><td>Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61(12):4766&#8211;72.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR111_27</td><td>BibArticle</td><td>Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002;25(3):207&#8211;17.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1097/00002371-200205000-00003>10.1097/00002371-200205000-00003</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, FirstPage, Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR112_27</td><td>BibArticle</td><td>Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR113_27</td><td>BibArticle</td><td>Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 2007;8(12):1002&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR114_27</td><td>BibArticle</td><td>Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006;16(1):141&#8211;6.</td><td><a href=http://dx.doi.org/10.3892/or.16.1.141>10.3892/or.16.1.141</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_1, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR115_27</td><td>BibArticle</td><td>Strassburg A, Pfister ED, Arning A, Nashan B, Ehrich JH, Melter M. Basiliximab reduces acute liver allograft rejection in pediatric patients. Transplant Proc 2002;34(6):2374&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/S0041-1345(02)03276-1>10.1016/S0041-1345(02)03276-1</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, Author_FamilyName_2, ArticleTitle, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR116_27</td><td>BibArticle</td><td>Furtado GC, de Lafaille Curotto MA, Kutchukhidze N, Lafaille JJ. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med 2002;196(6):851&#8211;7.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1084/jem.20020190>10.1084/jem.20020190</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR117_27</td><td>BibArticle</td><td>Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8(2):132&#8211;42.</td><td><a href=http://dx.doi.org/10.1053/jlts.2002.30302>10.1053/jlts.2002.30302</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR118_27</td><td>BibArticle</td><td>Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205&#8211;16.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR119_27</td><td>BibArticle</td><td>Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42(8):1031&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/j.ejca.2006.01.026>10.1016/j.ejca.2006.01.026</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, IssueID, Year, Author_FamilyName_1, FirstPage, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR120_27</td><td>BibArticle</td><td>Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14(10):3060&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-08-0126>10.1158/1078-0432.CCR-08-0126</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, IssueID, ArticleTitle, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR121_27</td><td>BibArticle</td><td>Jones RL, Cunningham D, Cook G, Ell PJ. Tumour vaccine associated lymphadenopathy and false positive positron emission tomography scan changes. Br J Radiol 2004;77(913):74&#8211;5.</td><td><a href=http://dx.doi.org/10.1259/bjr/19323466>10.1259/bjr/19323466</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, ArticleTitle, Author_FamilyName_1, FirstPage, IssueID, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR122_27</td><td>BibArticle</td><td>Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12(3 Pt 1):869&#8211;77.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-1574>10.1158/1078-0432.CCR-05-1574</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, ArticleTitle, VolumeID, Year, IssueID</td><td>CrossRef</td></tr><tr><td>CR123_27</td><td>BibArticle</td><td>Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13(13):3776&#8211;82.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-0588>10.1158/1078-0432.CCR-07-0588</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, IssueID, VolumeID, Author_FamilyName_2, ArticleTitle, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR124_27</td><td>BibArticle</td><td>von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7(5):1181&#8211;91.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>